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ABSTRACT
Background
The molecular mechanisms by which PROS1 mutations result in protein S deficiency are still
unknown for many of the mutations, particularly for those that result in a premature termination
codon. The aim of this study was to analyze the functional relevance on mRNA and protein
expression of 12 natural PROS1 mutations associated with protein S deficiency.
Design and Methods
Five mutations were nonsense, three were small frameshift deletions, one was c.258,259AG>GT
at the 3’ end of exon 3, one was p.M640T and the last two were c.-7C>G and p.L15H, found in
double heterozygosis as [c.-7C>G;44T>A]. The apparently neutral variant p.R233K was also ana-
lyzed. PROS1 cDNA was assessed by reverse transcriptase polymerase chain reaction of platelet
mRNA. Expression of mutant proteins was determined by site-directed mutagenesis and analy-
ses of transiently transfected PROS1 mutants in COS-7 cells.
Results
Only cDNA from the normal allele was observed from the five nonsense mutations, the frameshift
deletion c.1731delT and from c.258,259AG>GT. Both the normal and the mutated alleles were
observed from [c.-7C>G;44T>A], c.187,188delTG and p.M640T. Transient expression analyses
of PROS1 mutants whose mRNA was normally expressed revealed greatly reduced secretion of
p.L15H and c.1272delA, mild secretion values of p.M640T and normal secretion levels of c.-
7C>G and, as expected, p.R233K.
Conclusions
Whereas the main cause of quantitative protein S deficiency associated with missense mutations
is defective synthesis, stability or secretion of the mutated protein, the main mechanism for the
deficiency associated with mutations that generate a premature termination codon is not the syn-
thesis of a truncated protein, but the exclusion of the mutated allele, probably by nonsense-medi-
ated mRNA decay.
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Introduction
Protein S (PS) is a vitamin K-dependent plasma glycopro-
tein with anticoagulant and antithrombotic properties that
plays a crucial role in the regulation of coagulation.1 PS acts
as a co-factor for activated protein C in the inactivation of
procoagulant factors Va and VIIIa, which are essential for
thrombin generation.2 PS also has activeted protein C-inde-
pendent anticoagulant properties by directly inhibiting the
tenase and prothrombinase complexes.3 Besides its con-
firmed role as an anticoagulant protein, recent findings
suggest that PS may also have other important roles in cel-
lular processes and inflammation.4 Native PS is a multi-
domain protein that contains a signal peptide, a γ-car-
boxyglutamic acid-containing domain, a thrombin-sensi-
tive region, four epidermal growth factor-like domains and
a C-terminal domain that is homologous to the laminin A
globular-like domains.1 Mature PS circulates in plasma as a
single chain, 635-amino acid protein with a molecular
weight of approximately 75 kDa. In human plasma,
approximately 60% of PS forms a non-covalent equimolar
complex with the β-chain of C4BP that is inactive as acti-
vated protein C co-factor.5
PS deficiency (OMIM: +176880) is a recognized genetic
risk factor for thrombosis.1 It is an autosomal dominant
trait with incomplete penetrance and variable clinical and
biochemical expression which affects 2% to 8% of
patients with thrombosis in Caucasian populations.6
According to plasma levels of total and free PS antigen and
to the functional activity of PS, three types of PS deficien-
cy have been proposed. Type I is a quantitative deficiency
characterized by reduced levels of total and free PS antigen,
as well as anticoagulant activity; type II is a qualitative
deficiency characterized by normal levels of PS antigen but
reduced anticoagulant activity; type III PS deficiency,
which may be considered as a mild quantitative deficien-
cy,7 is characterized by normal levels of total PS antigen but
reduced levels of free PS antigen and activity. The throm-
botic risk associated with heterozygous type I PS deficien-
cy is between 2.5 and 10-fold higher than in the general
population.6,8
The PS gene (PROS1; Gene ID: 5627) spans 101 Kb of
genomic DNA in the centromeric region of chromosome3.
It is composed of 15 exons that are transcribed in 3.5 Kb of
mRNA (NM_000313).9 There are over 200 PROS1 defects
that segregate with PS deficiency in familial studies10 but
the molecular mechanisms by which these mutations
reduce plasma PS levels have been analyzed in fewer than
one third of them. Furthermore, while most studies have
been focused on the analysis of recombinant PROS1 mis-
sense mutations11-15 or mRNA analyses from splice-site
mutations,16-25 the effect on mRNA expression of muta-
tions that generate a premature termination codon has
been analyzed for only six nonsense or frameshift PROS1
mutations.26-31 Analysis of the functional effects of PROS1
mutations will improve the knowledge of the mechanisms
underlying PS function. The purpose of this study was to
analyze the functional relevance, both at RNA and protein
levels, of 12 natural PROS1 mutations associated with




All the mutations analyzed (Table 1) had been identified
in the heterozygous state in Spanish patients with quanti-
tative PS deficiency associated with venous thrombotic
disease.7,32 All patients gave their informed consent to par-
ticipation in this study and all procedures were reviewed
and approved by the ethics committee for clinical research
of the Ciutat Sanitària i Universitària de Bellvitge (CSUB).
Table 1. Mutations analyzed in this study. 
Mutation Amino acid changes Mean plasma PSb
HUGO Previous HUGO Previous Location Total Free PSDc Ref.
nomenclature nomenclaturea nomenclature nomenclaturea mean±SD (n) mean±SD (n) deficiency
[c.-7C>G;44T>A] [c.143C>G;193T>A]d None + p.L15H None + L-27H Exon 1 56±4     (2) 21±3        (2) I 32
c.178G>T c.324G>T p.E60X E19X Exon 2 52±13   (5) 23±7        (5) I 32
c.187,188delTG c.333,334delTG p.C63QfsX1 Frameshift, 23X Exon 2 53±8     (8) 28±6        (8) I 7
c.258,259AG>GT c.404,405AG>GT p.V87F V46F Exon 3 53±11  (17) 23±12     (17) I 7
c.698G>A c.844G>A p.R233K R192K Exon 7 91±16    (6) 77±19      (6) Nonee 32
c.835C>T c.981C>T p.Q279X Q238X Exon 8 57±15 (17) 18±10     (17) IF 7
c.1001C>G c.1147C>G p.S334X S293X Exon 10 39±12  (13) 17±6       (13) I 7
c.1272delA c.1418delA p.K424KfsX22 Frameshift, 405X Exon 11 57±19   (2) 22±1        (2) I-III 32
c.1351C>T c.1497C>T p.R451X R410X Exon 12 59±11   (5) 22±6        (5) I-III 32
c.1518G>A c.1664G>A p.W506X W465X Exon 13 60±10   (2) 17±1        (2) I-III 32
c.1731delT c.1877delT p.F577LfsX15 Frameshift, 551X Exon 14 60±20   (3) 29±6        (3) I-III 32
c.1919T>C c.2065T>C p.M640T M599T Exon 15 65±10   (3) 28±3        (4) I 32
aNomenclature based on the nucleotide and amino acid numbering of Schmidel et al.9 bMean values, as a percentage of the value in a normal plasma pool, from all het-
erozygotes for each mutation.  cMutation co-segregates with: I, type I PS deficiency; I-III, both type I and type III PS deficiency in the same pedigree. dThese two mutations
were identified in double heterozygosis in the same PROS1 allele. ep.R233K mutation was identified in a type III PS deficiency pedigree but it did not co-segregate with
the deficient phenotype: only two out of six heterozygotes had type III PS deficiency. fp.Q279X was identified in three type I pedigrees and in one pedigree with type I-III
PS deficiency. 
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Here, we have adopted HUGO recommendations for
mutation nomenclature (http://www.hgvs.org/mutnomen/).
Previous nomenclature, based on the mature protein, is
also shown in Table 1.
PROS1 mRNA studies
PROS1 mRNA was analyzed from patients who were
heterozygotes for both the mutation and at least one tran-
scribed PROS1 polymorphism (Table 2), in which the
allele associated with the mutation was known from pre-
vious segregation studies in each pedigree.7,32 Isolated total
RNA from frozen peripheral blood platelets 33 was reverse
transcribed by use of random hexamer primers and the
First Strand cDNA Synthesis Kit (Amersham Biosciences,
Uppsala, Sweden). For each patient, 50 ng of PROS1
cDNA were amplified by polymerase chain reaction (PCR)
with primers overlapping two contiguous exons upstream
and downstream of the mutation site (available upon
request). Amplified products were analyzed by agarose gel
electrophoresis and DNA sequencing in an ABI377 DNA
sequencer.
The PROS1 polymorphisms c.2001A>G (p.P667, dbSNP
rs#6123) and c.2551C>A (at the 3’UTR region,
rs#9681204) were analyzed by amplification of the cDNA
fragment containing exon 15 and restriction analysis with
BstXI (c.2001A>G) and AvaII (c.2551C>A).
Site-directed mutagenesis and expression of
recombinant PS variants 
Human PS cDNA subcloned in pcDNA3.1 was used as
the template for mutagenesis (primers available upon
request), as previously described.11 Mutant constructs
were confirmed by full cDNA sequencing. All PROS1
cDNA expression vectors were transcribed and translated
in vitro using the TNT®Coupled Reticulocyte System
(Promega, Madison, WI, USA). [35S-Met] synthesized
polypeptide chains were analyzed using 7.5% sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE), fixed, dried and revealed by autoradiography. For
transient expression of recombinant PS, COS-7 cells were
grown in Dulbecc'os modified Eagles’s medium (Gibco-
BRL, Gaithersburg, MD, USA) supplemented with 10%
(v/v) fetal bovine serum (Gibco-BRL), 2 mM glutamine,
100 units/mL penicillin and 100 µg/mL streptomycin and
maintained at 37 ºC in 5% CO2. Cells were co-transfected
by the DEAE-dextran method11 with 2.0 µg of mock vec-
tor, wild type (wt) or mutant PS constructs, 0.5 µg of the
β-galactosidase and 0.5 µg of the secreted alkaline phos-
phatase (SEAP, Clontech, Palo Alto, CA, USA) control vec-
tors. These control vectors were used for normalizing
transfection efficiency of recombinant PS in the culture
medium and in the cellular extracts, respectively. After 24
hours of transfection, the medium was changed to serum-
free medium supplemented with 10 mg/L of vitamin K1,
harvested 48 hours later and concentrated 10-fold.11
Soluble cell extracts were prepared by lysing cells in potas-
sium phosphate buffer 100 mM pH 7.3, 20% (v/v) Triton
X-100 and 1 mM dithiothreitol. At least two independent
experiments were performed in triplicate, except for the
[c.-7C>G;44T>A] double mutant experiment that was per-
formed once.
Western blot analysis 
Western blot of 2.5 µg of concentrated media and 3.25
µg of soluble cell extract proteins separated by 7.5% SDS-
PAGE under reduced conditions was analyzed by using a
rabbit polyclonal antibody against human PS (DAKO,
Glostrup, Denmark). Inmunoreactive electrophoretic
bands were detected by enhanced chemiluminiscence
(ECL AdvanceTM, Amersham) using a VersaDoc® 5000
Imager (BioRad, Hercules, CA) and quantified by Quantity
One® software (BioRad). In all assays, 25 ng of commercial
purified human plasma PS (Enzyme Research
Laboratories, Swansea, UK) were also included. SEAP in
the concentrated media was quantitatively assayed with
the Great EscAPe SEAP Chemiluminescent Kit (Clontech).
Table 2. Results of mRNA expression studies by reverse-transcriptase polymerase chain reaction.
Alleles in genomic DNA Alleles in cDNA
Mutation Amino acid PSD PROS1 SNPc PROS1 SNPc Mutated allele
chnage deficiencya mutationb c.2001A>G c.2551C>A Phased mutationb c.2001A>G c.2551C>A exclusion
c.-7C>G;44T>A] None + p.L15H I CT/GA AG - G CT/GA AG - NO
c.178G>T p.E60X I GT AG - G G A - YES
c.187,188delTG p.C63QfsX1 I TG/delTG - CA - TG/delTG - CA NO
c.258,259AG>GT p.V87F I AG/GT AG - A AG G - YES
c.835C>T p.Q279X I CT - CA A C - C YES
c.1001C>G p.S334X I CG AG - A C G - YES
c.1351C>T p.R451X I-III CT AG - G C A - YES
c.1518G>A p.W506X I-III GA AG - A G G - YES
c.1731delT p.F577LfsX15 I-III T/delT - CA C T - A YES
c.1919T>C p.M640T I CT AG - A CT AG - NO
aMutation co-segregates with: I, type I PS deficiency;I-III, both type I and type III PS deficiency in the same pedigree. bPROS1 mutation alleles in the amplified genomic
or cDNA fragments, as determined by DNA sequencing. cc.2001A>G or c.2551C>A PROS alleles in the amplified genomic or cDNA fragments, as determined by restric-
tion fragment length polymorphism analysis. dPhase (SNP allele associated with mutation) was established from segregation analysis in each pedigree.  
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Relative amounts of PS were normalized for the correspon-
ding SEAP values from culture media and actin/β-galatosi-
dase values from cell lysates. 
PS enzyme-linked immunosorbent assay
Wild-type and mutated PS in culture media were quan-
tified by ELISA using the Asserachrom® total and free pro-
tein S kits (Diagnostica Stago, France)  with some modifi-
cations. Briefly, 25 µg of total protein in phosphate-
buffered saline were used in both assays. Moreover, a stan-
dard curve of 150, 100, 50, 12.5 and 6.25 ng of purified
human plasma PS (Enzyme Research Laboratories) in
phosphate-buffered saline was prepared (Online
Supplementary Figure S1). All secreted PS values were nor-
malized for transfection efficiency as previously described
and quantified through the standard curve. At least two
independent experiments were performed in triplicate.  
Results
mRNA analysis of PROS1 mutations
Electrophoretic analysis of amplified PROS1 cDNA from
the patients revealed normal-sized fragments in all cases,
thus excluding the presence of stable mRNA with exon
skipping or other splicing alterations that could significant-
ly alter cDNA size. As indicated in Table 2, direct sequenc-
ing of amplified cDNA fragments revealed the absence of
the mutated allele in cDNA sequences from heterozygotes
for c.178G>T, c.258,259AG>GT, c.835C>T, c.1001C>G,
c.1351C>T, c.1518G>A, and c.1731delT mutations.
Furthermore, exclusion of the mutated allele was con-
firmed by restriction fragment length polymorphism
analysis of the transcribed polymorphisms c.2001A>G and
c.2551C>A in heterozygotes for at least one of these poly-
morphisms and the disease-associated mutation. This
analysis showed that only the allele associated with the
wild type sequence, but not the one associated with the
mutation, was present in the amplified cDNA fragment
(Table 2). Mutated and normal alleles were both observed
in cDNA sequences from [c.-7C>G;44T>A], c.187,
188delTG and c.1919T>C heterozygotes.
Transient expression analysis of PS mutants
Transient expression analysis of PROS1 mutants in
COS-7 cells was performed for [c.-7C>G;44T>A] and
p.M640T mutations that did not result in allelic exclusion
(Table 2), and for c.1272delA (not available for mRNA
studies) and p.R233K mutations. The effect of the single
mutants c.-7C>G and c.44T>A (p.L15H) was also ana-
lyzed. Although mRNA from c.187,188delTG was present,
we did not consider it necessary to analyze this PS mutant
that was expected to result in a truncated protein of only
64 residues. As shown in Figure 1, in vitro transcription-
translation of all PS mutants, except c.1272delA, revealed
[35S-Met]-labeled proteins of 68 kDa, which is the molecu-
lar weight of native PS without post-translational modifi-
cations. cDNA containing the c.1272delA mutation was
translated into a 49 kDa protein, which is the molecular
weight of the truncated protein (p.K424KfsX22) that is
expected to result from this frameshift mutation. 
As illustrated in Figure 2, western blot analyses of PS
mutants in COS-7 cell extracts indicated that the elec-
trophoretic mobility of p.M640T, p.R233K and c.-7C>G PS
was similar to that of wild-type PS. No band or, in some
experiments a faint one, was observed from [c.-
7C>G;44T>A] and p.L15H (c.44T>A) mutants. As in the in
vitro transcription–translation, a 49 kDa band was observed
from the p.K424KfsX22 mutant. In culture media, bands
with the same electrophoretic mobility as that of wild-type
PS were observed from the p.M640T, p.R233K and c.-
7C>G mutants. A faint band, which could be due to back-
ground COS-7 PS, was observed from p.K424KfsX22, [c.-
7C>G;44T>A] and p.L15H mutants, thus indicating the
absence of significant amounts of secreted proteins.
Mean normalized results of the semi-quantitative densit-
ometric analysis of the recombinant PS electrophoretic
bands in the cell culture media and in the cell extracts
showed that, in soluble cell extracts, PS from p.L15H and
[c.-7C>G;44T>A] mutants was absent or undetectable
(below 2% of wild-type PS). Values from p.K424KfsX22
truncated protein were 33±14% of wild-type PS. In con-
trast, the value from the p.M640T mutation was signifi-
Figure 1. In vitro transcription-translation of wild-type and mutat-
ed PS. Autoradiography of 7.5% SDS-PAGE of [35S]methionine-
labeled wild-type (wt) and mutated PS, translated in a reticulocyte
system. According to the molecular weight marker run in the gel,
on the right we indicate the molecular weights corresponding to
native PS (68 kDa), to the luciferase control (61 kDa) and to the
p.K424KfsX22 mutant (49 kDa), without post-translational modi-
fications. 
Figure 2. Western blot analysis of transiently expressed wild-type
and mutated PS in COS-7 cells. Western blot of purified human
plasma PS (hPS), wild-type (wt) and mutated PS secreted from
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cantly higher than the wild-type PS (155±11%). p.R233K
and c.-7C>G PS relative values were very similar to wild-
type PS (105±10% and 105±11%, respectively). In culture
media, PS p.K424KfsX22 was undetectable and p.L15H and
[c.-7C>G;44T>A] mutants showed low relative expression
values of 21±11% and 21±5% respectively, while the value
for p.M640T was half that of the wild-type (42±6%).
Finally, the relative PS values obtained for p.R233K and c.-
7C>G were similar to wild-type PS (109±4%
and105±14%).
Quantification of mutant PS secretion by ELISA
In order to confirm the western blot results, PS in the cul-
ture media was quantified by ELISA. As shown in Figure 3,
the results obtained (which were similar for total and free
PS ELISA) agreed well with those calculated from the
western blots for secreted PS. The lowest secretion values
(around 10% of wild-type PS) were obtained with the
p.K424KfsX22 and p.L15H mutants, and with the double
mutant [c.-7C>G;44T>A]. Between 40% and 50% of wild-
type PS was obtained with the p.M640T mutant. Protein
concentrations similar to wild-type PS were obtained with
the c.-7C>G and p.R233K mutants.
Discussion
Quantitative PS deficiency is usually associated with dif-
ferent types of PROS1 mutations that impair PROS1 gene
expression by several mechanisms related to DNA tran-
scription, mRNA processing, protein synthesis, stability
and secretion pathways. Nevertheless, the molecular
mechanism by which a given PROS1 mutation results in
quantitative PS deficiency is largely unknown. In this con-
text, this study was aimed at analyzing the effect on
mRNA and protein expression of 12 natural PROS1 muta-
tions associated with inherited quantitative PS deficiency
in Spanish pedigrees. An apparently neutral variant
(p.R233K) was also analyzed. Eight of these mutations are
nonsense or frameshift deletions that create a premature
termination codon. We, therefore, first determined their
expression at the mRNA level in order to analyze whether
they were subjected to nonsense-mediated mRNA decay,
a mechanism that degrades spliced mRNA that premature-
ly terminates translation and, consequently, prevents the
synthesis of potentially toxic proteins.34 The remaining
mutations were missense or regulatory mutations. Their
expression, as well as that of the nonsense mutations not
subjected to nonsense-mediated mRNA decay or whose
RNA could not be obtained, was analyzed at the protein
level. 
Analysis of cDNA sequences revealed the absence of
detectable amounts of the mutated allele from heterozy-
gotes for the five nonsense mutations, the frameshift dele-
tion c.1731delT (p.F577LfsX15) and the splice site and mis-
sense mutation c.258,259AG>GT (p.V87F), at the 3’ end of
exon 3. In the case of p.R451X and p.W506X, this was in
agreement with previous reports.26,28 Interestingly, all the
nonsense mutations that showed allelic exclusion, but
p.Q279X, are localized more than 50 nucleotides upstream
of an exon-exon junction. By contrast, c.187,188delTG,
which results in a premature termination codon at position
23, at 40 nucleotides from the junction between exons 2
and 3, is expressed at the mRNA level, as are the double
Figure 3. PS values of secreted recombinant PS, as measured by ELISA. Mean and standard error values, in ng/mL after normalization
for transfection efficiency, of secreted wild-type (wt) and mutated PS to the COS-7 cell culture media. Dark bars represent values
obtained with the free PS ELISA and light bars represent values obtained with the total PS ELISA assay. * Statistically significant differ-
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mutant [c.-7C>G;44T>A] and p.M640T. This agrees with
the 50 bp nonsense-mediated mRNA decay rule, which
states that premature termination codons that are followed
by an intron more than 50-55 nucleotides downstream
generally elicit nonsense-mediated mRNA decay.35 The
only mutation that does not follow the 50 bp nonsense-
mediated mRNA decay rule is c.835C>T (p.Q279X), at
only 12 bp upstream of the exons 8 and 9 junction. Though
the mechanism by which this mutation elicits nonsense-
mediated mRNA decay is unknown, in silico analysis with
the ESE-finder (http://exon.cshl.org/ESE)36 and the RESCUE-
ESE (http://genes.mit.edu/burgelab/rescue-ese)37 programs
revealed that c.835C>T abolishes a strong exon splicing
enhancer site for SF2/ASF and reduces the score for SC35
and SRp40 splicing factors. This could result in defective
splicing of intron 8, exon skipping, frameshift and intro-
duction of another premature termination codon.
Unfortunately, we could not test this hypothesis because
of the lack of availability of new fresh blood samples need-
ed to perform mRNA studies in a medium that inhibits
nonsense-mediated mRNA decay. Similarly, the absence of
mutated mRNA from c.258,259AG>GT indicates that
what causes PS deficiency is not the p.V87F substitution
that would result from this mutation if normally spliced,
but an alteration of the normal splicing of intron 3. This
agrees with the observation that this mutation reduces the
consensus value of the wild type donor splice site of intron
3 to a value lower than the one calculated for the
c.259G>C (p.V87L) mutation,7 which also results in
reduced mRNA expression.18
Since it was confirmed that [c.-7C>G;44T>A] and
p.M640T are not affected by nonsense-mediated mRNA
decay, their functional consequences, as well as those of
c.1272delA and p.R233K, were analyzed by means of tran-
sient transfection experiments in COS-7 cells. According to
the results obtained, we can cluster these mutations into
three groups: c.-7C>G and p.R233K with normal secretion
values, p.M640T which showed mildly reduced secretion
values, and p.L15H and p.K424KfsX22 which showed
undetectable secretion of the mutated protein. 
In the first group, the amounts of c.-7C>G and p.R233K
recombinant PS were similar to those of the wild-type PS,
thus indicating similar levels of synthesis and secretion.
This indicates that these mutant proteins are neutral vari-
ants of PROS1.10 In the case of p.R233K this was not sur-
prising, given the conservative nature of the amino-acid
replacement.1 The p.M640T mutation resulted in a 60%
reduction of protein secretion compared to that obtained
with wild-type PS but, by contrast, there was 40% more
mutant PS than wild-type PS in the cell extract. This sug-
gests that the mutant protein is normally synthesized but
accumulates in the cell, probably because of a secretion
and degradation defect caused by the synthesis of a struc-
turally abnormal protein, as already postulated for the sub-
stitution of the highly conserved hydrophobic Met 640
residue of the second laminin A globular domain β-strand
by a polar one.1
The lowest amounts of PS were obtained with muta-
tions p.L15H, the double mutant [c.-7C>G;44T>A] and
c.1272delA (p.K424KfsX22); the protein was absent or
present at very low levels in both the cell extract and the
cell media. These results indicate that these mutations
cause quantitative PS deficiency by reduced synthesis or
increased clearance of the mutant proteins. Furthermore,
the fact that c.-7C>G showed normal PS secretion, indi-
cates that PS deficiency in the [c.-7C>G;44T>A] double
heterozygotes is caused by the c.44T>A (p.L15H ) muta-
tion. As recently reviewed,1 the substitution of a polar
residue for a hydrophobic one in the signal peptide com-
promises its properties as a signal sequence for correct
membrane translocation and protein secretion. With
regard to the c.1272delA mutant, we detected some trun-
cated p.K424KfsX22 mutant protein in the cell extract.
Since no mRNA expression studies could be performed,
we cannot exclude that this mutation results in nonsense-
mediated mRNA decay but if it does not, it would also
result in quantitative PS deficiency, probably because the
truncated protein is degraded intracellularly.
We also observed a good correlation between recombi-
nant PS secretion and plasma PS levels in the heterozy-
gotes for the mutations analyzed. Thus, while p.R233K
was found in patients with normal PS levels, heterozy-
gotes for p.M640T showed mean free (28±3.4%) and, par-
ticularly, total (65±9.5%) PS values higher than the mean
values (21±9.5 for free PS and 53±13.7 for total PS) in 74
heterozygotes for mutations that result in a more severe
secretion defect, such as p.L15H or c.1272delA, or that are
subjected to nonsense-mediated mRNA decay.
Furthermore, the fact that heterozygotes for four of these
more severe mutations show either type I or type III PS defi-
ciency phenotypes suggests that, at least in these pedi-
grees, the PS deficiency phenotype is unrelated to the
PROS1 mutation genotype. 
In summary, the present results indicate that whereas
the main mechanism for quantitative PS deficiency associ-
ated with missense mutations is impaired synthesis, stabil-
ity or secretion of the mutated protein, mutations that
result in a premature termination codon result in a quanti-
tative PS deficiency mainly because of exclusion of the
mutated allele, probably by nonsense-mediated mRNA
decay.
Authorship and Disclosures
Conception and design of the study: BH, PGF, MPR and
NS; acquisition and/or analysis of data: BH, XM, MCM,
GN, PD, PGF, MPR and NS; drafting the article: BH, MPR
and NS; critical revision of the article: all authors; all
authors approved the final, submitted version of the man-
uscript. The authors reported no potential conflicts of
interest.
B.Hurtado et al. 
| 580 | haematologica | 2008; 93(4)
References
1. Garcia de Frutos P, Fuentes P,
Hurtado B, Sala N. Molecular basis
of protein S deficiency. Thromb
Haemost 2007;98:543-56.
2. Dahlback B. Factor V and protein S
as cofactors to activated protein C.
Haematologica 1997;82:91-5.
3. van Wijnen M, Stam JG, van't Veer
C, Meijers JC, Reitsma PH, Bertina
RM, et al. The interaction of protein
S with the phospholipid surface is
essential for the activated protein C-
independent activity of protein S.
Thromb Haemost 1996;76:397-403.
4. Hafizi S, Dahlback B. Gas6 and pro-
tein S. Vitamin K-dependent ligands
for the Axl receptor tyrosine kinase
subfamily. FEBS J 2006; 273:5231-
44.
5. Dahlbäck B. Haemostasis and
Thrombosis. Churchill Livingstone,
Edingburgh, 1994;671-98.
6. Faioni EM, Valsecchi C, Palla A,
Taioli E, Razzari C, Mannucci PM.
Free protein S deficiency is a risk
factor for venous thrombosis.
Thromb Haemost 1997;78:1343-6.
7. Espinosa-Parrilla Y, Morell M, Souto
JC, Tirado I, Fontcuberta J, Estivill X,
et al. Protein S gene analysis reveals
the presence of a cosegregating
mutation in most pedigrees with
type I but not type III PS deficiency.
Hum Mutat 1999;14:30-9.
8. Simmonds RE, Ireland H, Lane DA,
Zoller B, Garcia de Frutos P,
Dahlback B. Clarification of the risk
for venous thrombosis associated
with hereditary protein S deficiency
by investigation of a large kindred
with a characterized gene defect.
Ann Intern Med 1998;128:8-14.
9. Schmidel DK, Tatro AV, Phelps LG,
Tomczak JA, Long GL. Organization
of the human protein S genes.
Biochemistry 1990;29:7845-52.
10. Gandrille S, Borgel D, Sala N,
Espinosa-Parrilla Y, Simmonds R,
Rezende S, et al. Protein S deficien-
cy: a database of mutations - sum-
mary of the first update. Thromb
Haemost 2000;84:918.
11. Espinosa-Parrilla Y, Yamazaki T, Sala
N, Dahlback B, de Frutos PG.
Protein S secretion differences of
missense mutants account for phe-
notypic heterogeneity. Blood 2000;
95:173-9.
12. Rezende SM, Lane DA, Zoller B,
Mille-Baker B, Laffan M, Dalhback
B, et al. Genetic and phenotypic
variability between families with
hereditary protein S deficiency.
Thromb Haemost 2002;87:258-65.
13. Tsuda H, Urata M, Tsuda T,
Wakiyama M, Iida H, Nakahara M,
et al. Four missense mutations iden-
tified in the protein S gene of throm-
bosis patients with protein S defi-
ciency. Effects on secretion and anti-
coagulant activity of protein S.
Thromb Res 2002;105:233-9.
14. Biguzzi E, Razzari C, Lane DA,
Castaman G, Cappellari A,
Bucciarelli P, et al. Molecular diversi-
ty and thrombotic risk in protein S
deficiency: The PROSIT study. Hum
Mutat 2005;25:259-69.
15. Okada H, Yamazaki T, Takagi A,
Murate T, Yamamoto K, Takamatsu
J, et al. In vitro characterization of
missense mutations associated with
quantitative protein S deficiency. J
Thromb Haemost 2006;4:2003-9.
16. Mustafa S, Pabinger I, Mannhalter
C. A frequent mutation in the pro-
tein S gene results in cryptic splicing.
Br J Haematol 1997;97:555-7.
17. Mustafa S, Pabinger I, Varadi K,
Halbmayer WM, Lechner K,
Schwarz HP, et al. A hitherto
unknown splice site defect in the
protein S gene (PROS1): the muta-
tion results in allelic exclusion and
causes type I and type III protein S
deficiency. Br J Haematol 1997;9
9:298-300.
18. Yamazaki T, Katsumi A, Okamoto
Y, Takafuta T, Tsuzuki S, Kagami K,
et al. Two distinct novel splice site
mutations in a compound heterozy-
gous patient with protein S deficien-
cy. Thromb Haemost 1997;77:14-20.
19. Beauchamp NJ, Daly ME, Makris M,
Preston FE, Peake IR. A novel muta-
tion in intron K of the PROS1 gene
causes aberrant RNA splicing and is
a common cause of protein S defi-
ciency in a UK thrombophilia
cohort. Thromb Haemost 1998;
79:1086-91.
20. Tatewaki H, Iida H, Nakahara M,
Tsuda H, Kinoshita S, Kanaji T, et al.
A novel splice acceptor site muta-
tion which produces multiple splic-
ing abnormalities resulting in pro-
tein S deficiency type I. Thromb
Haemost 1999;82:65-71.
21. Iida H, Nakahara M, Komori K,
Fujise M, Wakiyama M, Urata M, et
al. Failure in the detection of aber-
rant mRNA from the heterozygotic
splice site mutant allele for protein S
in a patient with protein S deficien-
cy. Thromb Res 2001;102:187-96.
22. Nakahara M, Iida H, Urata M, Fujise
M, Wakiyama M, Kinoshita S, et al.
A novel splice acceptor site muta-
tion of protein S gene in affected
individuals with type I protein S
deficiency: allelic exclusion of the
mutant gene. Thromb Res
2001;101:387-93.
23. Baroni M, Mazzola G, Kaabache T,
Borgel D, Gandrille S, Vigano'
D'Angelo S, et al. Molecular bases of
type II protein S deficiency: the
I203-D204 deletion in the EGF4
domain alters GLA domain func-
tion. J Thromb Haemost 2006;4:186-
91.
24. Mizukami K, Nakabayashi T,
Naitoh S, Takeda M, Tarumi T,
Mizoguchi I, et al. One novel and
one recurrent mutation in the
PROS1 gene cause type I protein S
deficiency in patients with pul-
monary embolism associated with
deep vein thrombosis. Am J
Hematol 2006;81:787-97.
25. D'Andrea G, Di Perna P, Brancaccio
V, Faioni EM, Castaman G, Cibelli
G, et al. A novel G-to-A mutation in
the intron-N of the protein S gene
leading to abnormal RNA splicing in
a patient with protein S deficiency.
Haematologica 2003;88:459-64.
26. Mustafa S, Pabinger I, Mannhalter
C. Protein S deficiency type I: iden-
tification of point mutations in 9 of
10 families. Blood 1995;86:3444-51.
27. Okamoto Y, Yamazaki T, Katsumi
A, Kojima T, Takamatsu J, Nishida
M, et al. A novel nonsense mutation
associated with an exon skipping in
a patient with hereditary protein S
deficiency type I. Thromb Haemost
1996;75:877-82.
28. Bustorff T, Freire I, Gago T, Crespo
F, David D. Identification of three
novel mutations in hereditary pro-
tein S deficiency. Thromb Haemost
1997;77:21-5.
29. Reitsma PH, Ploos van Amstel HK,
Bertina RM. Three novel mutations
in five unrelated subjects with
hereditary protein S deficiency type
I. J Clin Invest 1994;93:486-92.
30. Yamazaki T, Hamaguchi M,
Katsumi A, Kagami K, Kojima T,
Takamatsu J, et al. A quantitative
protein S deficiency associated with
a novel nonsense mutation and
markedly reduced levels of mutated
mRNA. Thromb Haemost 1995;
74:590-5.
31. Andersen BD, Bisgaard ML, Lind B,
Philips M, Villoutreix B, Thorsen S.
Characterization and structural
impact of five novel PROS1 muta-
tions in eleven protein S-deficient
families. Thromb Haemost 2001;
86:1392-9.
32. Espinosa-Parrilla Y, Morell M,
Borrell M, Souto JC, Fontcuberta J,
Estivill X, et al. Optimization of a
simple and rapid single-strand con-
formation analysis for detection of
mutations in the PROS1 gene: iden-
tification of seven novel mutations
and three novel, apparently neutral,
variants. Hum Mutat 2000;15:463-
73.
33. Chomczynski P, Sacchi N. Single-




34. Maquat LE. Nonsense-mediated
mRNA decay: splicing, translation
and mRNP dynamics. Nat Rev Mol
Cell Biol 2004;5:89-99.
35. Nagy E, Maquat LE. A rule for termi-
nation-codon position within
intron-containing genes: when non-
sense affects RNA abundance.
Trends Biochem Sci 1998;23:198-9.
36. Cartegni L, Wang J, Zhu Z, Zhang
MQ, Krainer AR. ESEfinder: a web
resource to identify exonic splicing
enhancers. Nucleic Acids Res
2003;31:3568-71.
37. Fairbrother WG, Yeh RF, Sharp PA,
Burge CB. Predictive identification
of exonic splicing enhancers in
human genes. Science 2002;297:
1007-13.
